louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00926042: Genotype and Phenotype Registry: Enrollment of Normal Control Subjects for Current and Future Research
Official title: TAP0307: Enrollment of Normal Control Subjects for Current and Future Research
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Healthy
volunteer
Healthy controls
Normal controls
Lead sponsor: Northwell Health
Sponsor class: OTHER
First posted: 2009-06-23
Enrollment: 4511
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: New York City/ Long Island metropolitan community

Brief summary: Registry program for volunteers who are willing to serve as control subjects in future research studies.

Detailed description: The registry is a collection of volunteers willing to participate as control subjects in research studies. Control subjects are people who do not have a specific disease; therefore they can serve a critical role as a comparison with people who have the disease or other characteristic being studied. Once registered, participants will be notified about studies they may be able to participate in as a control.

Participation requires:

1. signing a consent form
2. answering a short health survey
3. providing a DNA sample via a mouthwash kit

The registry allows scientists to select study participants based on whether or not they have a specific genetic change that may be relevant to a disease under investigation. Having the ability to access controls when needed is an extremely valuable resource that will speed up scientific discoveries.

Eligibility criteria: Inclusion Criteria:

* Generally healthy
* over age 18

Exclusion Criteria:

* under age 18

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Manhasset
country: United States
facility: The Feinstein Institute for Medical Research
state: New York
Study officials:
affiliation: Northwell Health
name: Peter K Gregersen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05361642: Regional Nasal Block and Dexmedetomidine in Endoscopic Sinus Surgery
Official title: Comparison Between Combined Regional Nasal Block and General Anesthesia Versus General Anesthesia With Dexmedetomidine During Endoscopic Sinus Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Drug Use
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-05-05
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose is to compare the efficacy of combined regional nasal block and general anesthesia versus general anesthesia with dexmedetomidine during endoscopic sinus surgery in optimizing intraoperative surgical field.

Detailed description: This study will be done to compare between two different techniques including regional nasal block and dexmedetomidine in optimizing intraoperative surgical field according to average category scale

Eligibility criteria: Inclusion Criteria:

* Patients of ASA I or ASA II physical status.
* Patients with age 18-65 years.

Exclusion Criteria:

* Patients with physical status ASA III, IV.
* Known allergic reactions to local anesthetics.
* Patients with history for cerebrovascular or coronary insufficiency.
* Patients with infection at the block site.
* Patients with coagulopathy.

Primary outcomes:
measure: Optimizing intraoperative surgical field
timeFrame: Up to 6 months
Secondary outcomes:
measure: Heart rate in beat per minute
timeFrame: Up to 8 months
measure: Blood loss in millilitres
timeFrame: Up to 8 months
measure: endtidal sevoflurane concentration in MAC%
timeFrame: Up to 8 months
measure: phentolamine requirements in milligrams
timeFrame: Up to 8 months
measure: Duration of anesthesia in minutes
timeFrame: Up to 8 months
measure: Pain assessment with visual analogue scale(VAS)
timeFrame: Up to 8 months
measure: Mean blood pressure in mmHg
timeFrame: Up to 8 months
measure: Duration of surgery in minutes
timeFrame: Up to 8 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Moustafa Rakha
Study officials:
affiliation: Ain Shams University hospitals
name: Nahed Effat Yossef Salama, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT00733642: Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
Official title: An Open Label, Single Dose Escalation Study Of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer's Disease
Keywords: antibody amyloid Alzheimer's Disease AD
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-08-13
Enrollment: 15
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.


Eligibility criteria: Inclusion Criteria:

* Male or female (of non-child bearing potential) subjects ages ≥50 years of age.
* Diagnosis of probable AD (of mild to moderate severity), consistent with criteria from both: NINCDS-Alzheimer's Disease and Related Disorders Association (ADRDA) and DSM-IV-TR.
* MMSE score of 16-26 inclusive.
* Rosen-Modified Hachinski Ischemia Score ≤4.
* On a stable dose of background cholinesterase inhibitors or memantine for at least 60 days prior to dosing.

Exclusion Criteria:

* Diagnosis or history of other dementia or neurodegenerative disorders.
* Diagnosis or history of clinically significant cerebrovascular disease.
* Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes.
* History of allergic or anaphylactic reactions.

Primary outcomes:
measure: To examine the safety and tolerability of a single dose of PF-04360365 in subjects with mild-to-moderate AD.
timeFrame: 6 months
Secondary outcomes:
measure: To characterize the pharmacokinetic profile of PF-04360365 following administration of an IV infusion in subjects with mild-to-moderate AD.
timeFrame: 6 months
measure: To evaluate the relationship of PF-04360365 plasma exposure and Aβ plasma exposure.
timeFrame: 6 months
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Pfizer Investigational Site
state: California
city: Eatontown
country: United States
facility: Pfizer Investigational Site
state: New Jersey
city: Oakhurst
country: United States
facility: Pfizer Investigational Site
state: New Jersey
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06890442: Skull Bon Variations in Patient with Congenital Unilatral Choanal Atresia
Official title: Associated Radiological Variations in the Skull Bones in Patients with Cong: Unilateral Choanal Atresia
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atresia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-03-24
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will include patients diagnosed with congenital unilateral choanal atresia (CUCA). The inclusion and exclusion criteria will ensure a well-defined and homogenous group for analysis.

Brief summary: Identify skull bone Associated Anomalies in patients with cngenital unilatral choanal atresia

Detailed description: Choanal atresia is a rare congenital disorder caused by a failure to develop the posterior nasal cavity (choana), resulting in a missing opening between the nasopharynx and the nasal cavities.It is the most common congenital anatomical abnormality of the nasal cavities with incidence ratio approximately 1/5000-7000 live births

Generally, choanal atresia may affect one or both Choanae, although most studies show that the unilateral form is more common than the bilateral one,and the incidence is higher in females than in males Children with unilateral choanal atresia are subject to unilateral breathing usually have late unilateral nasal obstruction, persistent ipsilateral rhinorrhea, and recurrent rhinosiusitis Previous studies have shown that the ratio of bone to membranous atresia is 9:1; although a detailed review of CT findings with histopathological studies showed that mixed-wall atresia is the most common and is present in 71% of cases, while in 29% of cases we found a pure bone wall Computer tomography (CT) is presently the golden standard in diagnostics of nasal cavity diseases; thus, it can be applied successfully as a tool for assessing anatomical structures

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of Congenital Unilateral Choanal Atresia

Exclusion Criteria:

Patients with severe craniofacial syndromes

Primary outcomes:
measure: Radiological Variations in Skull Bones in Patients with Congenital Unilateral Choanal Atresia: A Cross-Sectional Study"
timeFrame: 10_12 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
name: Ahmed Ragab Sayed, Lecturer
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kwong KM. Current Updates on Choanal Atresia. Front Pediatr. 2015 Jun 9;3:52. doi: 10.3389/fped.2015.00052. eCollection 2015.
Clinical trial NCT01761942: Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa
Official title: A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Anorexia Nervosa
Keywords: omega-3 fatty acids
anorexia nervosa
efficacy
safety
Lead sponsor: Institute of Psychiatry and Neurology, Warsaw
Sponsor class: OTHER
First posted: 2013-01-07
Enrollment: 60
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether omega -3 fatty acids are effective and safe in treating anorexia nervosa.

Detailed description: 10-week, randomized, placebo-controlled, parallel-group study to compare the efficacy and safety of omega-3 fatty acids with placebo in the treatment of anorexia nervosa. Patients will be randomly assigned to blinded study treatment. Double-blind treatment will be preceded by a medication washout period of 1-28 days if necessary. Some patients may be taking anti-depressants or anti-psychotics, e.g. fluoxetine, prior to admission to the study. In such case the wash out period will depend on the medical treatment (dependent on the drug given) given prior to qualification to the study. Patient will be treated as inpatients during 10 weeks of the study. The study will recruit female inpatients with anorexia nervosa (aged 12 to 19 years), with DSM-IV and ICD-10 diagnosis of anorexia nervosa.BMI below 5 percentile and EAT-26 score \> 30 is required at both screening and randomization.

Eligibility criteria: Inclusion Criteria:

* Anorexia nervosa (DSM IV,ICD-10)
* Female
* Age 12-19
* Written informed consent given by patient and his parents

Exclusion Criteria:

* Lack of informed consent

Primary outcomes:
measure: Omega-3 fatty acids are superior to placebo in increasing BMI at day 70 compared with baseline
timeFrame: day 70th
Secondary outcomes:
measure: reducing EAT -26
timeFrame: day 70th
measure: changes in CGI
timeFrame: day 70th
measure: change in HDRS
timeFrame: day 70 th
measure: changes in BDI
timeFrame: day 70th
measure: changes in YBOCS
timeFrame: day 70 th
measure: changes in YBOCS
timeFrame: day 70th
measure: adverse events
timeFrame: 70 days time
measure: clinical laboratory tests
timeFrame: day 70 th
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Institute of Psychiatry and Neurology,
state: Mazowieckie
Study officials:
affiliation: Institute of Psychiatry and Neurology, Warsaw
name: Agnieszka Piróg-Balcerzak, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05201742: Incentive Spirometer and Inspiratory Muscle Trainer
Official title: A Comparative Study of Incentive Spirometer Versus Inspiratory Muscle Trainer on Pulmonary Function in Patients With Parkinsonism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Keywords: Parkinson disease
Incentive spirometer
Inspiratory muscle trainer
Pulmonary functions
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2022-01-21
Enrollment: 18
Sex: ALL
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients suffering from parkinsonism have respiratory function abnormalities. This study compared the effects of incentive spirometer and inspiratory muscle trainer on pulmonary functions in patients with parkinsonism.

Detailed description: The participants were recruited according to the inclusion and exclusion criteria. Participants were divided into two groups - incentive spirometer and inspiratory muscle trainer. These trainings were performed for 6 weeks duration. Several outcome measures related to pulmonary function tests were measured before and after the intervention.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed as having Parkinsonism Disease by the Neuro physician.
* Duration of Parkinson's Disease ≥ 5 years.
* Patients with the age of 65 to 80 years.
* Hoen and Yahr classification within 1 to 3.
* Both males and females were included.
* Patients who were able to comprehend the commands.
* Patients who were willing to participate.

Exclusion Criteria:

* Patients having any cardiovascular and pulmonary disorders.
* History of smoking currently or in the past.
* Psychological Impairment.
* Insufficient verbal/intellectual understanding.
* Patients with unstable vital parameters.
* Those unable to perform pulmonary function tests (PFT) because of anatomical abnormalities or clinical signs of dementia.

Primary outcomes:
measure: Maximum inspiratory pressure (MIP)
timeFrame: 6 weeks
measure: 6-minute walk distance (6 MWD)
timeFrame: 6 weeks
measure: Forced vital capacity (FVC)
timeFrame: 6 weeks
measure: Forced expiratory volume in 1 second (FEV1)
timeFrame: 6 weeks
measure: Peak Expiratory Flow Rate (PEFR)
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: King Saud University
Study officials:
affiliation: King Saud University
name: Masood Khan, M.P.Th
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03540342: Evaluation of One-stop Strategy of EVAR and PCI
Official title: Evaluation of the Strategy of "One-stop" Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Coronary Artery Disease
Aortic Atherosclerotic Disease
Keywords: coronary artery disease
aortic atherosclerotic disease
one-stop
percutaneous coronary intervention
endovascular aortic repair
Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor class: OTHER
First posted: 2018-05-30
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is designed to evaluate the safety and effectiveness of the "one-stop" endovascular intervention strategy for patients with concomitant coronary artery disease and aortic atherosclerotic disease. It is a registration study, which will consecutively enroll at least 50 patients with at least 30 subjects receiving one-stop strategy.

Detailed description: It is a registration study, at least 50 patients will be consecutively enrolled and then be allocated into one-stop strategy group or staging strategy group with at least 30 subjects receiving one-stop strategy. In one stop strategy group, percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR). In staging strategy group, PCI will be performed several days after EVAR. The safety and effectiveness will be assessed between the two groups untill 1 year after the operation. The economic index will be evaluated.

Eligibility criteria: Inclusion Criteria:

* Aged from 18 years to 75years, male or female;
* Aortic atherosclerotic disease with the indication of EVAR;
* Coronary heart disease with the indication of PCI;
* Provided informed consent.

Exclusion Criteria:

* Acute aortic dissection
* Acute coronary syndrome
* Dysfunction of coagulation system
* Patients with gastrointestinal hemorrhage
* Known allergy to contrasts or antiplatelet drugs
* Renal dysfunction (GFR≤60ml/min)
* Patient with multi-branch coronary preferred CABG

Primary outcomes:
measure: Treatment-Emergent Adverse Events
timeFrame: 12 months
Secondary outcomes:
measure: Operative success rate
timeFrame: 12 months
measure: Average in-patient time
timeFrame: 12 months
measure: Average cost during hospitalization
timeFrame: 12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese Academy of Medical Sciences, Fuwai Hospital
state: Beijing
Study officials:
affiliation: Chinese Academy of Medical Sciences, Fuwai Hospital
name: Yi-Da Tang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06396442: Patient Worries Previous to Dental Treatment
Official title: Patient Worries Previous to Dental Treatment: a Multicenter Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Patients
Keywords: dental treatment
worry
Lead sponsor: Aula Dental Avanzada
Sponsor class: OTHER
First posted: 2024-05-02
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who, after being informed about the treatment to be performed and about the research, agreed to answer the questionnaire would be included. The questionnaire should be answered just after receiving the clinical information on their treatment and before receiving the financial information on the treatment.

Brief summary: This is a multicenter cross-sectional study that aims to provide a snapshot of the experience of patients before starting dental treatment.

Detailed description: Although the information is of limited duration, it could represent a descriptive view of a particular context of the dental profession in Spain. This qualitative information on patients' concerns may help the clinician to categorize patients' concerns, facilitate communication, and manage their expectations before initiating treatment.

Patients attending 6 different clinics in Spain consecutively for two years constitute the study sample. Questionnaires will be given to patients who consented to participate in the study, prior to the start of treatment. In addition to the questionnaire, additional demographic data will also be recorded.

The data will be analyzed statistically and appropriate conclusions will be drawn.

Eligibility criteria: Inclusion Criteria:

* All patients who are going to receive dental treatment.

Exclusion Criteria:

* None

Primary outcomes:
measure: Worry or anxiety
timeFrame: Day 0
measure: Fear of anesthesia
timeFrame: Day 0
measure: Fear of pain
timeFrame: Day 0
measure: Fear of postoperative pain
timeFrame: Day 0
measure: Fear of chewing disability
timeFrame: Day 0
measure: Treatment aesthetic effect
timeFrame: Day 0
measure: Economic cost
timeFrame: Day 0
measure: Fear of contagion
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Alicante
country: Spain
facility: Clínica Dental Esteve
Study officials:
References:
Clinical trial NCT05755542: Long-Covid in Patients Post Rehabilitation Treatment and Reintegration Into Everyday Life
Official title: Occurrence of Long-Covid in Patients After Inpatient Rehabilitation Due to Acute Covid-19 Infection. How Easy is it for Patients to Return to Everyday Life and Work After Inpatient Rehabilitation Due to Acute Covid-19-infection?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Long COVID
Lead sponsor: Rehazentrum Walenstadtberg
Sponsor class: OTHER
First posted: 2023-03-06
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men and Women over 18 years of age who have been treated at Rehazentrum Walenstadtberg after being hospitilized primarily because of an acute Covid-19 infection

Brief summary: The aim of the first study is to investigate how often a long Covid syndrome occurs after an inpatient rehabilitation due to previous hospitalization because of after acute Covid and whether there might be a connection with the severity during acute illness. 3 clusters of acute cases have been identified to be studied with regard to the long-term symptoms

1. Mild course (medication, oxygen)
2. Moderate course (IPS-IMC with NIV but without intubation)
3. Severe course (intubation)

The aim of the second study is to use a catamnestic survey and subsequent evaluation of the information to gain an insight into the existing functional deficits relevant to everyday life and restriction of the ability to participate in the workplace after rehabilitation treatment. The assessment of functional deficits is carried out in relation to:

1. Deficits in everyday skills (ADLs)
2. Restrictions in the ability to participate in the profession.

Detailed description: All patients who had been infected with Walenstadtberg after acute Covid infection were included.

Patients were hospitalized for inpatient rehabilitation in the period from 01.04.2020 to 30.06.2022.

A written follow-up survey was carried out with regard to a possible persistent long Covid symptoms and possible persistent deficits in everyday skills and Restrictions in the ability to participate in the profession. There are 2 cohort studies.

Eligibility criteria: Inclusion Criteria:

* \>18 years of age
* treated at a rehabilitation facility after being hospitilized for covid-19 infection
* complete questionnaire
* written consent to use collected data

Exclusion Criteria:

* \< 18 years
* incomplete questionnaire

Primary outcomes:
measure: Occurance of Symptoms pointing at Long-Covid after rehabilitation treatment
timeFrame: 2 years
measure: Occurance of deficits in managing everyday life and work after covid infection
timeFrame: 2 years
Secondary outcomes:
measure: reinfection with covid-19 after rehabilition treatment
timeFrame: 2 years
measure: Impact of Covid-19 infection on quality of life
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Rehazentrum Walenstadtberg
name: Stefan Bachman, Prof.
role: STUDY_DIRECTOR
References: